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Abstract
Objective Owing to the widespread use of abdominal
imaging studies the detection rate of solid renal masses
has increased, and an accurate characterisation of imaging
features of renal masses has become more essential for case
management.
Method and results MR imaging (MRI) and computed
tomography (CT) are frequently used modalities for detection
and differentiation of renal masses. This article gives a review
of imaging characteristics of benign and malignant renal
masses, discussing their appearance in CT and MR imaging.
Advanced MR techniques like diffusion-weighted imaging
and apparent diffusion coefficient (ADC) mapping, which
have shown promising results in the differentiation between
benign and malignant renal lesions, will be introduced.
Conclusion MRI and CT are useful in the characterisation
and estimation of the prognosis for renal masses.
Keywords Humans.Kidney diseases.Kidney masses.
Magnetic resonance imaging.Computed tomography
Introduction/epidemiology
The detection rate of renal masses has increased in the last
decades owing to the widespread use of CT and MRI [1].
Therefore, an accurate characterisation of renal masses is
essential to ensure appropriate case management. Renal
masses can be divided into cystic and solid lesions [2]. The
most common are cysts in up to 27% of patients over
50 years [3]. CT- or MRI-enhancing masses are classified as
solid or complex cystic. Eighty-five percent of expansive
solid masses are malignant [4]. Therefore, a solid, enhanc-
ing mass must be considered malignant unless proven
otherwise. Renal cell carcinoma (RCC) is the most common
malignant tumour with a rising incidence of about 3% per
year since 1975. The most common subtype of RCC is the
clear cell RCC (synonym: common or conventional RCC)
with 65% of renal cortical tumours. Further subtypes are
papillary (basophilic and eosinophilic) and chromophobe
RCCs with about 25% of renal cortical tumours. Clear-cell
RCC causes 90% of metastases of all renal malignancies [5,
6]. Other malignant masses include transitional cell carci-
noma (TCC), lymphoma (primary and more frequent
secondary), metastases from carcinoma and primary/sec-
ondary sarcoma. Primary tumours of the lung, breast and
gastrointestinal tract are the most common sources of renal
metastases [7].
Benign tumours account for approximately 20% of all
solid renal cortical tumours, and renal oncocytoma is the
most common solid tumour type [8, 9].
Non-neoplastic renal masses include inflammatory pseu-
dotumours with and without abscess formation, renal
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coexistent xanthogranulomatous pyelonephritis [10, 11].
Examination protocol
The examination protocols of CT and MR are abundantly
described elsewhere and we refer to the current literature
[12–15].
CT A renal CT is performed in 3–4 phases: the native,
arterial (20- to 40-s delay), the venous (100- to 150-s delay)
and the excretory phase (180- to 300-s delay). In order to
reduce radiation exposure, different low-dose protocols and
a reduction of contrast phases have been reported [14].
MRI MR examinations are performed with dedicated body
(array) coils and must include T1-weighted gradient-echo
(GRE, in- and opposed-phase) and T2-weighted turbo spin
echo (TSE) sequences. Dynamic gadolinium-enhanced
images are obtained in late arterial (20-s delay), nephro-
graphic (80-s delay) and excretory phases (180-s delay). As
in CT, MR urograms can be obtained ideally with thick-slab
single-shot T2-weighted TSE.
The use of furosemide for forced diuresis and a further
distension of the collecting system and for a consecutive
reduction in the T2* effects of the concentrated contrast
material is optional [13, 15].
Concerning diffusion-weighted imaging (DWI) [16],
different authors have shown the value of apparent
diffusion coefficients (ADCs) for characterising renal
masses. In these studies, renal tumours had significantly
lower ADCs compared with benign cysts, and solid
enhancing tumours had significantly lower ADCs compared
with non-enhancing necrotic or cystic regions [17, 18].
They concluded that ADC measurements may aid in
differentiating subgroups of renal masses, particularly
benign cystic lesions from cystic renal cell cancers (Fig. 1).
Fig. 1 Presentation of
diffusion-weighted images
(DWI; b-value: 800) and
apparent diffusion coefficient
(ADC) maps in different
entities: Upper row demon-
strates bright signal on DWI
(a; b-value: 800) and low signal
on an ADC map (b) in the case
of a clear cell renal cell
carcinoma (RCC), with hetero-
geneous pattern on T2-weighted
image (c). The signal decrease
in the ADC map is considered to
be a marker of high cell density
in the tumour. Middle row
demonstrates bright signal on
the ADC map (d) in a polycystic
kidney. T2-weighted image
shows different intensities in the
cysts (arrow in e). The cysts
were graded as Bosniak I–II.
Lower row demonstrates bright
signal on DWI (f; b-value: 800)
in a case of xanthogranuloma-
tous pyelonephritis (see also
Fig. 10). The ADC map (g)
showed no signal loss, which
could be explained by interstitial
oedema but no indication of
increased cell densitiy, which
can be helpful in the
differentiation of an inflamma-
tory from a neoplastic tissue
alteration. Contrast-enhanced
T1-weighted image shows
strong enhancement of the
pelvic wall (arrow in h)
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These imaging parameters should be helpful in the
characterisation of renal masses focussing especially on
differentiation between cystic and solid lesions [19].
I. Detection of lesions: Because of better soft-tissue
contrast the tumour detection rate seems better with
MR, but according to the literature, especially in renal
lesions with a diameter of more than 2 cm, CTshows a
similar detection rate [20].
II. Size, shape and contour: Renal masses with a
diameter of <4 cm are defined as small renal
masses. The smaller the mass is, the greater the
chance that it is benign [1]. In a report 46% of
masses that were less than 1 cm in diameter were
benign, as were 22% of those that were 1 to 2.9 cm
in diameter and 20% of those that were 3 to 3.9 cm
in diameter [21]. Among malignant masses, greater
size correlates with higher pathological grade [4, 22–
24]. As in many other malignancies, unsharpened
borders of a solid tumour are nearly always a sign of
malignancy with the exception of inflammatory
cysts and bleeding angiomyolipoma.
III. Growth rate: Growth rate of small renal masses is
typically low (2 to 4 mm per year) and seems to be
similar for masses subsequently found to be malignant
(renal cell carcinoma) and those found to be benign
(oncocytoma) [26]. Masses without growth were
about as likely to be malignant (83%) as those that
grew (89%) [27]. There are no definable clinical or
radiological characteristics to predict growth [22].
IV. Tissue consistency: Areas of macroscopic fat within a
renal mass are usually diagnostic of angiomyolipoma
with a very few exceptions. In rare cases the additional
presence of calcification in a fat-containing lesion can
indicatea malignant condition [28, 29]. A small number
of angiomyolipomas do not contain fat and remain a
diagnostic dilemma because differentiation from malig-
nant renal neoplasm is impossible [30]. On the other
hand, a few cases of RCC have been reported where
macroscopic fat and calcifications were present [31].
Presence of central necrosis may be helpful in the diagnosis
of RCC, a finding that is very rare in angiomyolipoma [32].
Intratumoral haemorrhage has a variable appearance
depending on the stage of degradation of the component
blood products. Subacute to chronic haemorrhage generally
demonstrates high signal intensity on both T1- and T2-
weighted images. Chronic haemorrhage, containing hae-
mosiderin, is typically hypointense on both T1- and T2-
weighted images [33]. Intratumoral bleeding is sometimes
hard to depict with CT, while calcifications can hardly be
seen on MRI.
V. Imaging characteristics of common renal masses
The imaging characteristics of common renal masses are
listed in Table 1.
1. Simple/Complex cyst:
The Bosniak classification system is used to graduate cystic
masses: [34]
& Bosniak I: Benign simple cyst, hairline-thin wall, no
septa, calcifications or solid components. Water density,
no contrast enhancement.
& Bosniak II: Benign cyst, may contain few hairline-thin
septa. Fine calcification or slightly thickened calcifica-
tion in wall or septa. Uniformly high-attenuation lesions
(<3 cm), sharply marginated, no enhancement, are
included in this group.
& Bosniak IIF: Increased number of hairline-thin septa.
Minimal enhancement in hairline-thin smooth septum
or wall, minimal thickening of the septa or wall.
Possibly thick and nodular calcification, no contrast
enhancement. No enhancing soft-tissue components.
Totally intrarenal nonenhancing high-attenuation renal
lesions that are 3 cm or larger are also included in this
category. These lesions are generally well marginated.
& Bosniak III: Indeterminate cystic masses with thickened
irregular walls or septa, enhancement can be seen.
& Bosniak IV: Clearly malignant cystic masses, addition-
ally with enhancing soft-tissue components adjacent to
but independent of the wall or septa.
CT It is helpful to differentiate category I, III and IV cysts.
Depending on the size and location, it is critical to
differentiate between complicated cysts of categories II
and III [35].
The so-called pseudoenhancement is defined as an
artificial elevation of the Hounsfield unit measurements of
a renal cyst measured on the contrast-enhanced CT images
and is thought to be secondary to the image reconstruction
algorithm used to adjust for beam-hardening effects. This
pseudoenhancement of small intraparenchymal cysts can
lead to an upgraded Bosniak cyst classification with major
implications for prognosis and clinical management. Also,
calcification and high-densitiy fluid of cysts can compli-
cate the differentiation between Bosniak II and III cysts
[2, 31].
MRI Simple cysts are homogeneous hyperintense lesions
with a thin wall on T2-weighted images (Fig. 2). Complex
cysts have septa and solid nodules with low signal on T2-
weighted images due to haemorrhagic or proteinaceous
content (Fig. 3). On T1-weighted images simple cysts are
hypointense relative to the normal renal parenchyma.
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546 Insights Imaging (2011) 2:543–556Fig. 2 MRI presentation of
typical image characteristics of a
simple cyst (Bosniak I): hyper-
intense on T2-weighted images
(T2; arrow in a), hypointense on
T1-weighted images (T1; arrow
in b), no contrast media
enhancement in T1 (arrow in c),
and bright on the diffusion-
weighted images (ADC map;
arrow in d)
Fig. 3 MRI presentation of
typical image characteristics of a
complex cyst (Bosniak IV):
hyperintense with hypointense
areas on T2- (arrow in a),
hypo- and isointense in
T1- (arrow in b), focal contrast
media enhancement on
T1-weighted (arrow in c), and
heterogeneous pattern on the
ADC map (arrow in d)
Insights Imaging (2011) 2:543–556 547Increased signal may indicate haemorrhage or proteinaceous
fluid [32].
Israel et al. compared CT and MRI in the evaluation of
cystic renalmasses byusing theBosniak classification system.
CT and MRI findings were similar for most cystic renal
masses. In some cases, however, MRI may depict additional
septa, thickening of the wall and/or septa, or enhancement,
which may lead to an upgraded Bosniak classification [34].
Nevertheless, it is helpful to be aware that the Bosniak criteria
have been defined and validated for CT and not for MRI.
Therefore, the Bosniak criteria have to be used carefully used
in relation to magnetic resonance imaging.
Despite the use of contrast-enhanced ultrasound (CEUS)
in the differential diagnosis of renal masses still being
under debate, complex cysts of the kidney are probably the
best indication for renal CEUS. CEUS helps to depict
blood flow perfusion within the wall, septa and solid
components. Furthermore, CEUS is applicable in patients
with impaired kidney function or ureteric obstruction,
which may be contraindications for contrast-enhanced CT
or MRI [36].
2. RCC (clear cell or common type)
The Fuhrman grading system categorises clear cell
carcinoma into four groups (Fig. 4). Its use has been
expanded to other subtypes (e.g., papillary RCC). The
following tumours have a poorer prognosis: high-grade
carcinoma, clear cell RCC, sarcomatoid and rhabdoid
differentiations of clear cell RCC [37, 38].
CT Ninety percent of clear cell RCCs are hypervascular
with a heterogeneous enhancing pattern of mixed enhancing
solid soft-tissue components and low-attenuation necrotic or
cystic areas [13, 39]. Clear cell carcinomas can be predom-
inantly cystic. Renal vein tumour thrombus can be seen with
aggressive higher stage tumours.
MRI Appearance varies depending on the presence of
haemorrhage and necrosis. On T1-weighted images clear
cell RCC most frequently demonstrates a signal intensity as
renal parenchyma. Central necrosis is typically seen as a
homogeneous hypointense area in the centre of the mass on
Fig. 4 Multimodal presentation
of a common type RCC on CT
and MRI: CT (upper row):
isodense in the native phase
(arrow in a), hypervascular in
the arterial phase with areas of
necrosis (arrow in b) and early
wash-out in the venous phase
(arrow in c). MRI (middle and
lower row): heterogeneous
appearance on T2-weighted
(arrow in d) and T1-weighted
native (arrow in e) because of
haemorrhage and necrosis,
heterogeneous pattern on the
ADC map (arrow in f), hyper-
enhancement in the arterial
phase with areas of necrosis
(arrow in g), early wash-out in
the venous phase (arrow in h),
and a tumour thrombus with
contrast media enhancement
reaching the renal vein and
inferior vena cava (arrow in i)
548 Insights Imaging (2011) 2:543–556T1-weighted images. On T2-weighted images an increased
signal intensity is found. Loss of signal within the solid
portions of the clear cell RCCs on opposed-phase images
compared with in-phase images is due to cytoplasmic fat
and has been observed in up to 60% of these tumours [30,
32]. Clear cell RCC tends to be hypervascular, with
heterogeneous enhancement during the arterial phase [32].
3. RCC (papillary and chromophobe type)
PapillaryRCCaccountsforapproximately10%–15%ofall
RCCs and may be multifocal (Fig. 5). Chromophobe renal
tumours account for approximately 4–11% of RCCs [32].
CT Seventy-five percent of papillary RCCs are hypovascular,
and 90% of all papillary tumours demonstrate a homogeneous
or peripheral enhancement pattern. Chromophobe tumours
often demonstrate a moderate degreeofenhancement [13, 39].
MRI Papillary RCC demonstrates homogeneous low signal
intensity on T2-weighted images with homogeneous low-
level enhancement after i.v. gadolinium administration.
Chromophobe RCC may show cystic changes within a
solid tumour. Central necrosis may be absent even in very
large chromophobe carcinomas. Imaging features can be
identical to those of clear cell RCC [32, 40, 41].
4. TCC
Transitional cell carcinoma (Fig. 6) accounts for 90% of
all tumours arising from the renal pelvic urothelium and is
divided into papillary (more common) and non-papillary
types. TCC is frequently multifocal and may involve any
part of the collecting system. Haematogenous spread is less
common than with RCC, but lymphatic metastases occur
early. Only 2–4% of patients with bladder cancer develop
upper tract TCC, but 40% of patients with upper tract TCC
develop bladder cancer. Diagnosis of upper tract TCC is
heavily dependent on imaging. Stage is the main predictor
of prognosis in comparison to tumour grade [32, 42].
CT CT urography allows assessment of a non-functioning
kidney that is superior to excretion urography and nodal
and distant metastases. The shape of the kidney is usually
preserved even in the presence of large tumours. Hydro-
nephrosis proximal to the lesion is usually present unless
the collecting system is completely filled by tumour. If the
renal sinus is obliterated by tumour, the appearance may
mimic the so-called faceless kidney [44].
MRI On T1-weighted images TCCs are typically isointense
relative to the renal medulla. Enhancement of a focal filling
defect in the collecting system is strongly suggestive of a
TCC. Differentiation between blood clots and enhancing
filling defects may be possible using subtracted data sets.
TCC is typically a hypo-enhancing mass, although focal
hyper-enhancement may occur.
T2-weighted images show hypointense filling defects in
the collecting system. Infiltrative TCC can be seen on
single-shot T2-weighted images as a hypointense soft-tissue
mass infiltrating the renal parenchyma.
5. Lymphoma
Extranodal spread of lymphoma (Fig. 7) often affects the
genitourinary system, with the kidneys being the most
commonly involved organs. Primary renal lymphoma is
rare, and non-Hodgkin’s lymphoma is much more common
than Hodgkin’s. Growth of lymphomatous cells occurs in
Fig. 5 Imaging presentation of
a papillary (upper row) and a
chromophobe (lower row) RCC.
Papillary RCC (a: CT venous
phase; b: T2-weighted; c:
T1-weighted, venous phase) as
well as chromophobe RCC
(d: CT native; e: CT, arterial
phase; e: CT, venous phase)
show a hypoenhancement in the
arterial (arrow in e) and venous
phase (arrows in a, c and f), and
they are often hypo-/isointense
on T2-w (arrow in b)i n
comparison to normal renal
parenchyma
Insights Imaging (2011) 2:543–556 549the interstitium, with the nephrons, collecting ducts and
blood vessels serving as a framework for tumour expan-
sion, which produces the following patterns [45]:
& multiple poorly enhancing masses (60%)
& retroperitoneal tumours directly invading the kidneys
(25–30%)
& infiltrative pattern with bilateral renal enlargement
without disruption of the renal contour and perirenal
soft-tissue masses
Fig. 6 Imaging presentation of an infiltrating papillary transitional
cell carcinoma (TCC) on CT (upper row; a–d) and MRI (lower row;
e–h). On CT there is an enhancing mass in the renal sinus surrounding
the neck of the middle calyx (arrows in a and b) with a filling defect
in the calyceal neck in the excretory phase (arrow in c) and a calyceal
amputation in the CT urogram (arrow in d). On MRI the dilated calyx
shows bleeding (arrow in e) and suspicious findings on diffusion-
weighted imaging (arrow in f) with a clearly detectable enhancing
mass along the calyceal neck (arrows in g and h)
Fig. 7 CT imaging presentation
(courtesy of Siegfried Schwab,
University Hospital Erlangen,
Germany; with permission) of
renal lymphoma with unilateral
(arrows in a–c) and bilateral
(arrows in d) hypoenhancing
focal masses with diffuse renal
swelling and perirenal oedema.
Small masses can be found in
the cortex and with signs of
infiltration of the perirenal space
(arrow in c)
550 Insights Imaging (2011) 2:543–556& cystic lesions and tumours predominantly affecting the
renal sinus and collecting system are uncommon
Image-guided percutaneous biopsy is essential for
diagnostic confirmation to avoid unnecessary nephrectomy.
Following treatment, imaging findings may resolve with
minimal residual scarring [32].
CT Contrast-enhanced CT remains the technique of choice
for the detection, diagnosis, staging and monitoring of renal
lymphoma [46, 47].
MRI Besides the morphological patterns already men-
tioned, lymphomatous masses are, relative to the renal
cortex, iso- or slightly hypointense on T1-weighted images
and hypointense on T2-weighted images. Minimal hetero-
geneous enhancement is seen on early and delayed
gadolinium-enhanced MR images in retroperitoneal masses
and renal involvement [32, 48].
6. Angiomyolipoma
Angiomyolipomas (Fig. 8) are hamartomas containing
varying proportions of fat, smooth muscle and thick-walled
blood vessels. Tumours larger than 4 cm carry an increased
risk of potentially life-threatening haemorrhage (Wunder-
lich syndrome), which has been reported in up to 10% of
these patients [32].
CT Lipid-containing angiomyolipoma can be easily
detected with CT.
However, angiomyolipoma may contain very small
quantities of fat, which can be overlooked if the mass is
not carefully evaluated. When a small amount of fat is
suspected in a renal mass, an unenhanced CT examination
with thin sections and, if necessary, a pixel analysis, is the
most sensitive test [31, 49].
Lipid-poor angiomyolipoma presents a diagnostic dilem-
ma and cannot be differentiated from RCC. Zhang et al.
Fig. 8 Imaging presentation of angiomyolipoma (AML) in CT (upper
and lower row) and MRI (middle row). On CT (upper row) lipid-
containing AML shows bulk fat in the native (arrow in a) and
moderate enhancement in the arterial (arrow in b), venous (arrow in c)
and excretory phase (arrow in d). On MRI (middle row) another lipid-
containing AML shows streaky signal alteration on in- and opposed-
phase T1-weighted imaging (arrows in e and f), heterogeneous pattern
with high signal intensity on TSE T2 (arrow in g), a moderate
enhancement on T1 (arrow in h), and a clear signal loss on the T1-
weighted image with fat saturation (arrow in i). On CT (lower row) a
lipid-poor AML is not clearly distinguishable from other renal masses
in the native (arrow in i) and venous phase (arrows in j and k)
Insights Imaging (2011) 2:543–556 551described a homogeneous pattern and a moderate enhance-
ment of lipid-poor angiomyolipomas [13].
MRI Lipid-containing angiomyolipomas show a higher
signal intensity than renal parenchyma on T1-weighted
images. Demonstration of bulk fat within an angiomyoli-
poma can be achieved by applying a selective fat-
suppression pulse. Opposed-phase imaging shows a char-
acteristic India ink artifact at the interface between the mass
and the normal renal parenchyma. The signal loss can be
helpful for the diagnosis of lipid-poor angiomyolipomas,
but clear cell RCC can also show small amounts of
intracellular fat. The presence of central necrosis suggests
the diagnosis of RCC, a finding that is very rare in
angiomyolipoma. Lipid-poor angiomyolipomas frequently
demonstrate homogeneous low signal intensity relative to
the renal parenchyma on T2-weighted images. Angiomyo-
lipomas can show different degrees of enhancement
depending on the amount of vascularised tissue components
they contain [32, 50, 51].
However, all the mentioned imaging characteristics are
not specific enough to make a confident diagnosis of a non-
fat-containing angiomyolipoma. In some cases, biopsy of
the renal mass may be indicated to make a definitive
diagnosis of an angiomyolipoma and to avoid surgery [31].
7. Oncocytoma
Oncocytomas (Fig. 9) account for 3–7% of solid renal
masses. They may be multicentric, bilateral or metachro-
nous in a minority of cases. A stellate central area of
fibrosis or hyalinised connective tissue with compressed
blood vessels, the so-called central scar, is observed in up to
54% of cases. Based on imaging findings a proper
differentiation between oncocytoma and RCC is not
possible [32].
CT Oncocytoma remains a diagnostic challenge. Zhang
et al. found that oncocytoma tended to show a homoge-
neous and hypervascular pattern. A central scar can be seen
in large oncocytoma [13].
MRI Appearance is variable and non-specific. Oncocytomas
are typically spheric and well-defined masses. Relative to the
renal cortex, they have lower signal intensity on T1-weighted
images in approximately 70% and higher signal intensity on
T2-weighted images in up to 67%. The central scar (when
present) can be seen as a stellate area of high signal intensity
on T2-weighted images and of low signal intensity on T1-
weighted images with delayed gadolinium enhancement. A
well-defined hypointense capsule can be seen surrounding the
tumour in almost one-half of renal oncocytomas. However,
the presence of a pseudocapsule is non-specific and can be
seen in up to 60% of RCCs as well [32, 52].
8. Pyelonephritis/abscess/xanthogranulomatous pyelone-
phritis/renal infarction
Bacterial pyelonephritis (PN) usually is an ascending
infection from the lower urinary tract and can affect one or
both kidneys. Haematogenous spread of bacteria is rare and
usually affects both kidneys.
Fig. 9 Imaging presentation of adenoma on CT (upper row) and MRI
(lower row) in one patient. CT shows a native isodense mass (arrow in
a) with a hyperenhancement in the arterial phase (arrow in b), and an
early wash-out in the venous (arrow in c) and excretory (arrow in d)
phases. MRI shows a non-lipid-containing mass on the in- and
opposed-phase T1-weighted imaging (arrows in e and f) with a
heterogeneous appearance in T2- (arrow in g) and a heterogeneous
contrast media enhancement in T1-weighted image (arrow in h).
Based on imaging features alone, this mass cannot be differentiated
from RCC
552 Insights Imaging (2011) 2:543–556Xanthogranulomatous pyelonephritis (XP) (Fig. 10)
results from severe chronic infection causing diffuse renal
destruction. Risk factors include female gender and
diabetes. Most patients have nephrolithiasis, and staghorn
calculi are found in 50% of patients. The more common
diffuse form is characterised by extensive involvement of
the renal parenchyma. The focal form of the disease may be
misinterpreted as a renal neoplasm; the presence of a
staghorn calculus, appropriate clinical presentation and the
characteristic imaging findings strongly suggest the diag-
nosis [32]. CT is helpful in the detection of calculi.
CT In the case of PN unenhanced CT may appear normal,
but acute bacterial nephritis most commonly manifests as
one or more wedge-shaped areas or streaky zones of lesser
enhancement that extend from the papilla to the renal
cortex. Abscesses can be identified in CT as round or
geographic low-attenuation collections with no central
enhancement, but an enhancing rim (pseudo-capsules with
wall thicknesses and frequent nodularity). Diminished
enhancement may surround the abscess (halo sign) during
the nephrographic phase. Extraparenchymal collections can
extend into adjacent structures (e.g., psoas muscle).
MRI The value of MR imaging for early diagnosis of
pyelonephritis is still under debate.
Heterogeneous enhancement of renal tissue can also be
seen with MR imaging. Probably DWI is helpful because of
its high senstivity in the detection of parenchymal oedema.
Magnetic resonance imaging findings of abscesses are
similar to those of CT and include renal oedema, haemor-
rhage, renal enlargement, abscesses and perinephric fluid
[53]. Abscess cavities show intermediate signal on T1-
weighted images and high signal intensity on T2-weighted
images. Cavity walls may show marked gadolinium
enhancement. Calculi may be seen as areas of signal void
within the collecting system [32, 54].
Renal infarction (RI) can have various causes, including
thromboembolism, renal artery thrombosis, vasculitis,
shock and trauma.
Fig. 10 Imaging presentation of
xanthogranulomatous pyelone-
phritis (XP) and bacterial
pyelonephritis (PN) on CT and
MRI: XP on CT (upper row): a
pelvic stone is clearly visible
with a diffuse thickening of the
pelvic wall, which shows
enhancement in the arterial
(arrow in a) and venous (arrow
in b) phase. The CT urogram
(arrow in c) shows the hydro-
nephrosis owing to an obstruc-
tion at the level of the uretero-
pelvic junction. XP on MRI
(middle row): the thickening of
the pelvic wall is clearly detect-
able on T1-weighted (arrow in
d) and T2-weighted (arrow in e)
images, and an enhancement of
the pelvic wall in T1 in the
venous (arrow in f) phase.
Contrast-enhanced MRI
urogram (g) enables a similar
presentation of the upper urinary
tract in comparison to the CT
urogram. PN on MRI (lower
row): ADC mapping shows a
decreased signal (arrow in h)
and DWI (b-value: 800) a
heterogeneous pattern of renal
parenchyma (arrow in i). In the
venous phase small non-
enhanced subcapsular areas are
detectable (arrow in j). MR
urogram shows no hydroneph-
rosis in this case of ascending
PN (arrow in k)
Insights Imaging (2011) 2:543–556 553CT CT shows a swelling of the kidney, usually with perirenal
fluid. Other findings are subcapsular haematoma, mass effect
or a focal area of renal enlargement, and a thickened renal
fascia. On post-contrast images a demarcation of the wedge-
shaped infarcted areas is possible. The ischaemic areas are
mainly located in the columns of the kidney contrary to
inflammatory alterations, which can be located in the renal
pyramids in the case of ascending infection.
MRI On T1- and T2-weighted MR images, the signal
intensity of the infarcted area is usually lower than that of
the non-infarcted area owing to interstitial oedema and
haemorrhage, with a loss of corticomedullary differentia-
tion. In the follow-up signal intensity increases progres-
sively with both sequences because of coagulation necrosis
and interstitial haemorrhage. Post-contrast T1-weighted
images clearly demonstrate wedge-shaped infarcted areas.
The non-infarcted portion of the involved kidney may have
higher signal intensity than the opposite uninvolved kidney
on T2-weighted images and post-contrast T1-weighted
images because of acute tubular necrosis and interstitial
oedema at the margin of the infarct or reperfusion injury.
With development of cortical atrophy and organising
fibrosis (after weeks) the signal intensity of the infarcted
area decreases again. The extent and distribution of the
infarcted areas at MR imaging correlate well with CT and
angiography [55].
VI. Clinical management/role of percutaneous renal mass
biopsy
renal mass
solid
not definitively 
benign
according to 
imaging studies
Bosniak I Bosniak II-IIf Bosniak III/IV > 4 cm 
patients <70 years
no major 
coexisting 
condition
good life 
expectancy
good surgical risk
< 4 cm 
patients >70 years
limited life 
expectancy
compromised 
renal function
poor surgical risk
Fig. 11 Clinical flow chart of
renal masses (modified
according to Gill et al. [19])
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patients with renal masses by depicting certain lesions that
do not require treatment. MRI and CT are useful for follow-
up, and helpful for planning specific surgical approaches. In
unclear solid lesions a percutaneous renal mass biopsy
(RMB) has to be considered. The use of RMB has
increased in recent years, despite concerns about safety,
accuracy and sampling errors [19]. New biopsy techniques
decrease the risk of tumour seeding, and overall morbidity
is low. Diagnostic sufficiency and accuracy of RMB are
now much higher in large-volume, experienced centres [56,
57]. Experienced users can achieve accurate diagnosis in
over 90%. Pretreatment RMB can significantly decrease the
number of unnecessary surgeries for benign disease and
assist in clinical decision-making, beyond documenting
renal involvement for patients with metastatic disease or
other systemic illnesses. Especially for elderly and unfit
patients who are possible candidates for active surveillance
and/or minimally invasive ablative therapies, RMB seems
to be a valuable tool. Finally, there is the potential for
stratifying the initial therapy of metastatic RCC by
histological subtype on needle biopsies [58]. Another study
group concluded that percutaneous renal needle core biopsy
has an acceptable sensitivity and specificity in the diagnosis
of renal masses. The major limitation of percutaneous core
biopsy is the technical failure that leads to insufficient
material for accurate diagnosis [56, 57].
Furthermore, diagnostic and therapeutic decisions de-
pend on the age and condition of the patient (see Fig. 11).
Conclusion
The technical developments in CT and MRI in the last
decade enable an excellent detection rate of renal masses.
Contrast-enhanced images allow differentiation between
cystic and solid renal lesions. Complex cystic and solid
lesions can be characterised further. Pretreatment percuta-
neous biopsy can significantly decrease the number of
unnecessary surgeries for benign disease and assist the
urologist in clinical decision-making, especially for elderly
and unfit patients who are possible candidates for active
surveillance and/or minimally invasive ablative therapies.
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